Summary:
A phase 2 study on the effectiveness and safety of MLR-1023 as an adjunctive treatment to people with Type 2 Diabetes and currently being treated with Metformin.
Qualified Participants Must:
• Be betweeen 18 and 75 years of age
•
Be diagnosed with Type 2 diabetes, and being treated with metformin
Qualified Participants May Receive:
Compensation is available for time and travel. Qualified participants may also receive investigational medication and study related treatment at no cost.